Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Next Previous
X
Search
Trial Profile

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA-203 (Primary) ; Carboplatin; Dacarbazine; Ipilimumab; Lifileucel; Nivolumab; Nivolumab/relatlimab; Paclitaxel; Pembrolizumab; Temozolomide
  • Indications Acral lentiginous melanoma; Malignant melanoma; Skin cancer; Uveal melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SUPRAME
  • Sponsors Immatics US

    • Most Recent Events

    • 16 Jan 2025 Status changed from not yet recruiting to recruiting.
    • 25 Dec 2024 Status changed from planning to not yet recruiting.
    • 18 Nov 2024 According to an Immatics media release, Immatics aims to submit a Biologics License Application (BLA) in early 2027 for full approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top